Wolfe Research Begins Coverage on Definium Therapeutics (NASDAQ:DFTX)

Equities researchers at Wolfe Research assumed coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a report released on Monday, Marketbeat Ratings reports. The brokerage set an “outperform” rating on the stock.

Several other equities analysts have also weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Definium Therapeutics in a report on Monday, February 2nd. Robert W. Baird set a $37.00 price target on Definium Therapeutics in a research report on Thursday, January 29th. Royal Bank Of Canada lifted their price objective on Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. JonesTrading initiated coverage on Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $34.20.

Definium Therapeutics Price Performance

DFTX opened at $17.45 on Monday. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $18.70. The firm has a 50-day moving average of $15.36 and a 200 day moving average of $12.69. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The firm has a market cap of $1.72 billion, a P/E ratio of -8.55 and a beta of 2.57.

Insider Transactions at Definium Therapeutics

In related news, CEO Robert Barrow sold 25,791 shares of Definium Therapeutics stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the sale, the chief executive officer owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel Karlin sold 5,600 shares of the firm’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the sale, the insider directly owned 425,025 shares in the company, valued at approximately $5,589,078.75. The trade was a 1.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 42,667 shares of company stock valued at $561,071. 2.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its holdings in shares of Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after buying an additional 6,148 shares during the last quarter. CWM LLC increased its stake in Definium Therapeutics by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after acquiring an additional 1,796 shares during the last quarter. Teacher Retirement System of Texas raised its position in Definium Therapeutics by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after purchasing an additional 1,400 shares in the last quarter. Geode Capital Management LLC lifted its stake in Definium Therapeutics by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after purchasing an additional 66,663 shares during the last quarter. Finally, Creative Planning boosted its holdings in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares in the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.